Inclusion Criteria:

- Histologically proven inoperable locally advanced or metastatic adenocarcinoma of the
stomach (including adenocarcinoma of the gastrooesophageal junction)

- Patient's age between 20 and 70 years old

- Measurable disease defined by RECIST criteria

- Patients with non-measurable disease could be enrolled in the phase I part of the
study

- ECOG performance status ≤ 1

- Hgb ≥ 8g/dL, WBC ≥ 3 x 109/L , neutrophils count ≥ 1.5 x 109/L , platelets ≥100 x
109/L, Creatinine clearance ≥50 mL/min, Total bilirubin ≤ 1.5 X UNL, AST, ALT and ALP
≤ 2.5 x UNL

- No prior chemotherapy or more than 6 months from adjuvant chemotherapy or
chemo-radiation

- Estimated life expectancy more than 3 months

- Written informed consent

Exclusion Criteria:

- Gastrointestinal bleeding

- Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's
discomfort

- CNS metastases

- History of hypersensitivity to fluoropyrimidines, docetaxel or platinum compounds

- Any previous chemotherapy or radiotherapy for advanced disease

- Patient pregnant or breast feeding, or planning to become pregnant within 6 months
after the end of treatment

- Patient (male or female) is not willing to use highly effective methods of
contraception (per institutional standard) during treatment and for 6 months (male or
female) after the end of treatment

- Known hypersensitivity reaction to the component of the treatment

- Active infection or malnutrition or bowel obstruction

- Legal incapacity or limited legal capacity

- Definite contraindications for the use of corticosteroids

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
evidence of interstitial lung disease on baseline chest CT scan

- Chronic inflammation of the bowel

- Clinically significant cardiovascular disease (including myocardial infarction,
unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
arrhythmia) ≤ 1 year before enrollment

- Medical or psychological condition which in the opinion of the investigator would not
permit the subject to complete the study or sign meaningful informed consent

- A second primary tumor other than non-melanoma skin cancer or in situ cervical cancer